Nordic acquires ex US rights to Bayer's antifibrinolytic after suspension
This article was originally published in Scrip
Executive Summary
The Nordic Group is to acquire from Bayer Healthcare the worldwide rights to the antifibrinolytic, Trasylol (aprotinin injection), outside the US.